The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

• Published in: Clinical genitourinary cancer 2018-02, Vol.16 (1), p.e223-e231
• Main Authors: Heinrich, Daniel, Bektic, Jasmin, Bergman, Andries M., Caffo, Orazio, Cathomas, Richard, Chi, Kim N., Daugaard, Gedske, Keizman, Daniel, Kindblom, Jon, Kramer, Gero, Olmos, David, Omlin, Aurelius, Sridhar, Srikala S., Tucci, Marcello, van Oort, Inge, Nilsson, Sten
• Format: Article
• Language: English
• Subjects: Bone metastases; Medicin och hälsovetenskap; Patient selection; Targeted alpha therapy; Treatment monitoring; Treatment sequence
• ISSN: 1558-7673; 1938-0682; 1938-0682
• DOI: 10.1016/j.clgc.2017.08.020

Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the first-line choice for many patients. The optimal patient profile for radium-223 in the modern setting, and its best use either in sequence or in combination with other approved agents are unclear, with few definitive guidelines available. This article reports on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring. Where agreement was reached, guidance on the optimal use of radium-223 is provided.